Takeda Pharmaceutical and BioSurfaces, an Ashland, Massachusetts-based biomedical research company, have entered into an agreement to initiate a research program designed to develop medical devices to treat patients with gastrointestinal (GI) diseases using BioSurfaces’ proprietary nanomaterial technology.

Under the joint research program, Takeda and BioSurfaces will explore therapeutic approaches for treating GI indications.  Takeda will provide scientific and technical expertise in gastroenterology while BioSurfaces will provide medical-device design and nanomaterial expertise and fabrication technology. Additional terms of the agreement were not disclosed.

BioSurfaces has developed a process for producing nanofibrous materials out of US Food and Drug Administration-approved polymers. BioSurfaces’ manufacturing process allows the incorporation of drugs or other bioactive agents directly into the nanofibers for localized release, according to the company.   

Source: Takeda Pharmaceutical